Tags

Type your tag names separated by a space and hit enter

Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis.
Expert Rev Gastroenterol Hepatol. 2016 Oct; 10(10):1083-1089.ER

Abstract

INTRODUCTION

Gastroesophageal reflux disease (GERD) is a common condition afflicting millions of patients, whose prevalence continues to rise owing to the aging population and increasing burden of comorbid conditions, such as obesity. Currently, the mainstay of therapy for GERD is treatment with proton pump inhibitors (PPIs), which have proven efficacy, safety, and tolerability. Despite this, a considerable number of patients have refractory symptoms to PPI therapy. Dexlansoprazole is a new addition to the class of PPIs, which has a unique dual delayed drug release system, which aims to address the current limitations of acid suppressive therapy by offering extended acid suppression and improved ease of administration. Areas covered: This manuscript covers the pharmacokinetics, pharmacodynamics, clinical efficacy, and regulatory approval of dexlansoprazole. Additionally, there is further discussion concerning the current market settings and the potential future impact of dexlansoprazole. Expert commentary: Overall, dexlansoprazole offers benefits in its ease of administration and proven efficacy in the healing, maintenance of erosive esophagitis, and symptomatic non-erosive GERD. Long-term, dexlansoprazole will likely find a niche market among patients who fail other acid suppressive therapy or who desire simplified administration for compliance concerns, but will likely come at a higher out of pocket expense than comparable generic PPIs.

Authors+Show Affiliations

a Department of Internal Medicine , Eastern Virginia Medical School , Norfolk , VA , USA.b Department of Internal Medicine, Division of Gastroenterology and Hepatology , Tulane University , New Orleans , LA , USA.c Department of Internal Medicine, Division of Gastroenterology , Eastern Virginia Medical School , Norfolk , VA , USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27580358

Citation

Oldfield, Edward C., et al. "Dexlansoprazole: Delayed-release Orally Disintegrating Tablets for the Treatment of Heartburn Associated With Non-erosive Gastroesophageal Reflux Disease and the Maintenance of Erosive Esophagitis." Expert Review of Gastroenterology & Hepatology, vol. 10, no. 10, 2016, pp. 1083-1089.
Oldfield EC, Parekh PJ, Johnson DA. Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis. Expert Rev Gastroenterol Hepatol. 2016;10(10):1083-1089.
Oldfield, E. C., Parekh, P. J., & Johnson, D. A. (2016). Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis. Expert Review of Gastroenterology & Hepatology, 10(10), 1083-1089. https://doi.org/10.1080/17474124.2016.1230496
Oldfield EC, Parekh PJ, Johnson DA. Dexlansoprazole: Delayed-release Orally Disintegrating Tablets for the Treatment of Heartburn Associated With Non-erosive Gastroesophageal Reflux Disease and the Maintenance of Erosive Esophagitis. Expert Rev Gastroenterol Hepatol. 2016;10(10):1083-1089. PubMed PMID: 27580358.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dexlansoprazole: delayed-release orally disintegrating tablets for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease and the maintenance of erosive esophagitis. AU - Oldfield,Edward C,4th AU - Parekh,Parth J, AU - Johnson,David A, PY - 2016/9/1/pubmed PY - 2016/9/1/medline PY - 2016/9/1/entrez KW - Dexilant KW - Dexlansoprazole KW - erosive esophagitis KW - gastroesophageal reflux disease KW - non-erosive reflux disease KW - proton pump inhibitor SP - 1083 EP - 1089 JF - Expert review of gastroenterology & hepatology JO - Expert Rev Gastroenterol Hepatol VL - 10 IS - 10 N2 - INTRODUCTION: Gastroesophageal reflux disease (GERD) is a common condition afflicting millions of patients, whose prevalence continues to rise owing to the aging population and increasing burden of comorbid conditions, such as obesity. Currently, the mainstay of therapy for GERD is treatment with proton pump inhibitors (PPIs), which have proven efficacy, safety, and tolerability. Despite this, a considerable number of patients have refractory symptoms to PPI therapy. Dexlansoprazole is a new addition to the class of PPIs, which has a unique dual delayed drug release system, which aims to address the current limitations of acid suppressive therapy by offering extended acid suppression and improved ease of administration. Areas covered: This manuscript covers the pharmacokinetics, pharmacodynamics, clinical efficacy, and regulatory approval of dexlansoprazole. Additionally, there is further discussion concerning the current market settings and the potential future impact of dexlansoprazole. Expert commentary: Overall, dexlansoprazole offers benefits in its ease of administration and proven efficacy in the healing, maintenance of erosive esophagitis, and symptomatic non-erosive GERD. Long-term, dexlansoprazole will likely find a niche market among patients who fail other acid suppressive therapy or who desire simplified administration for compliance concerns, but will likely come at a higher out of pocket expense than comparable generic PPIs. SN - 1747-4132 UR - https://www.unboundmedicine.com/medline/citation/27580358/Dexlansoprazole:_delayed_release_orally_disintegrating_tablets_for_the_treatment_of_heartburn_associated_with_non_erosive_gastroesophageal_reflux_disease_and_the_maintenance_of_erosive_esophagitis_ L2 - http://www.tandfonline.com/doi/full/10.1080/17474124.2016.1230496 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.